Hemodynamic and biochemical effects of AT1-receptor antagonist irbesartan in essential hypertension

Interactive effect of angiotensin II type 1 receptor (AGT1R) polymorphisms and plasma irbesartan concentration on antihypertensive therapeutic responses to irbesartan

“…The A1166C genetic variant is a functional SNP in the 3 0 -untranslated sequence, which may involve alternately spliced AGT1R mRNA transcripts and regulate gene expression level in the renin-angiotensin system [24][25][26][27]. It was shown that exogenous human Ang II increased BP more potently in patients with 1166AC than in those with 1166AA [28].…”

Comparison of the Angiotensin II Receptor Antagonist Irbesartan With Atenolol for Treatment of Hypertension

“…Results of previous studies of irbesartan have demonstrated a dose-dependent feedback increase in renin and AII levels and a blunting of the pressor effects of AII in healthy volunteers [13]. In hypertensive patients, irbesartan reduces blood pressure in a dose-related manner within 1 week [14,15]. Furthermore, the long plasma half-life of irbesartan (11-15 h) and sustained 24-h blood pressure control permit once-daily dosing [16][17][18].…”

24-Hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring

“…Once-daily administration of irbesartan to healthy subjects [4][5][6][7] and individuals with mild-to-moderate hypertension [8,9] increased renin levels and lowered blood pressure 24 h after dosing in a dose-dependent manner. In previous clinical studies, trough : peak ratios for office-measured seated diastolic blood pressure (SDBP) were > 50% with irbesartan doses greater than 50 mg once a day, suggesting that once-daily dosing could provide control of blood pressure over the full 24 h [9].…”

“…A previous randomized, double-blind, placebo-controlled, 7-day tolerability study with irbesartan suggested that 100 mg once a day, but not 25 mg once a day, significantly reduced 24 h systolic and diastolic ambulatory blood pressure (ABP) [8]. The present study was designed to determine the efficacy of irbesartan at oral doses of 75 mg once a day, 150 mg once a day, and 75 mg twice a day versus placebo in treating patients with mild-tomoderate hypertension assessed by 24 h ABPM, to confirm these effects by performing trough office blood pressure measurements, and to assess the safety and tolerability of these irbesartan regimens.…”